第二代牛痘疫苗——ACAM2000获FDA许可

FDA于2007—09-1对外公布其已批准新的牛痘疫苗——ACAM2000。该疫苗用于接种那些处于暴露于天花高风险的人群，以保护个体和群体免受生物恐怖主义者的袭击。该品将作为国家战略贮备药物被储存在美国疾病控制与预防中心（CDC）。

Monkeypox in humans:Transmission,pathophysiology,diagnosis,treatment,prevention,and all recent updates

The Centers for Disease Control and Prevention(CDC)is monitoring an epidemic of monkeypox infection in the United States.The outbreak is now global and more than 6900 cases have already been reported.There are 83 confirmed cases among children and adolescents,as shown in the report published on November 3,2022,in the USA.However,monkeypox in pediatric patients is still infrequent(<0.3%of total cases).Among cases in the United States,16 cases were in children<5 years,12 in the age group 5-12 years,and 55 cases in adolescents 13-17 years old.In the adolescent age group,89%were male.For children<12 years of age,close physical contact with an adult household with monkeypox was the primary exposure,but for adolescents,male-to-male sexual contact was found more frequently.The CDC advised United States healthcare providers to remain vigilant for patients with a rash resembling monkeypox,even if there is no history of travel to a country with high risk.This article summarizes the history and epidemiology of monkeypox with a specific emphasis on clinical features and management in pediatric patients.

国外新近批准主要新药（十九）

美FDA批准第二代天花疫苗ACAM2000 2007年9月1日，美国食品药品管理局（FDA）批准了Acambis有限公司的新抗天花疫苗ACAM2000，用于处在暴露于天花病毒高风险中人接种及在生物恐怖分子发动天花病毒攻击时保护相关人群。天花病毒作为一种高度触染性病毒，其具用作致死性生物恐怖武器的潜力，而ACAM2000已被美国疾病控制与预防中心（CDC）列作美国战略性国家医药储备之一且业采购了近2亿人次剂量。